Sanofi (NASDAQ:SNY) Position Boosted by Boothbay Fund Management LLC

Boothbay Fund Management LLC lifted its holdings in Sanofi (NASDAQ:SNY - Free Report) by 103.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 393,814 shares of the company's stock after purchasing an additional 200,346 shares during the period. Sanofi comprises 0.5% of Boothbay Fund Management LLC's holdings, making the stock its 26th biggest holding. Boothbay Fund Management LLC's holdings in Sanofi were worth $18,994,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in SNY. Abel Hall LLC raised its holdings in Sanofi by 1.8% during the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company's stock worth $530,000 after buying an additional 194 shares during the period. Providence Capital Advisors LLC increased its position in shares of Sanofi by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company's stock worth $2,653,000 after acquiring an additional 201 shares in the last quarter. Keudell Morrison Wealth Management raised its holdings in shares of Sanofi by 1.7% during the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company's stock valued at $624,000 after acquiring an additional 217 shares during the period. Bailard Inc. lifted its position in shares of Sanofi by 1.4% in the 4th quarter. Bailard Inc. now owns 16,359 shares of the company's stock valued at $789,000 after acquiring an additional 220 shares in the last quarter. Finally, Old Port Advisors boosted its stake in Sanofi by 0.6% in the 4th quarter. Old Port Advisors now owns 36,704 shares of the company's stock worth $1,770,000 after purchasing an additional 232 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Sanofi Stock Performance

Shares of SNY stock opened at $52.32 on Friday. Sanofi has a fifty-two week low of $45.80 and a fifty-two week high of $60.12. The stock's 50-day moving average is $54.53 and its two-hundred day moving average is $52.09. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The firm has a market cap of $132.17 billion, a P/E ratio of 21.01, a PEG ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The firm had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be given a $2.0369 dividend. The ex-dividend date is Friday, May 9th. This represents a dividend yield of 3.1%. This is a boost from Sanofi's previous annual dividend of $1.48. Sanofi's payout ratio is currently 57.14%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. BNP Paribas assumed coverage on Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 target price on the stock. Finally, The Goldman Sachs Group initiated coverage on Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $63.33.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.